Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies was written by Bezencon, Olivier;Heidmann, Bibia;Siegrist, Romain;Stamm, Simon;Richard, Sylvia;Pozzi, Davide;Corminboeuf, Olivier;Roch, Catherine;Kessler, Melanie;Ertel, Eric A.;Reymond, Isabelle;Pfeifer, Thomas;de Kanter, Ruben;Toeroek-Schafroth, Michael;Moccia, Luca G.;Mawet, Jacques;Moon, Richard;Rey, Markus;Capeleto, Bruno;Fournier, Elvire. And the article was included in Journal of Medicinal Chemistry in 2017.Recommanded Product: 40594-98-7 This article mentions the following:
The authors report the discovery and pharmacol. characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be neg. in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478 (N-(1-((5-cyanopyridin-2-yl)methyl)-1H-pyrazol-3-yl)-2-(4-(1-(trifluoromethyl)cyclopropyl)phenyl)acetamide)), which has been selected as a clin. candidate. In the experiment, the researchers used many compounds, for example, Ethyl 1H-1,2,3-triazole-5-carboxylate (cas: 40594-98-7Recommanded Product: 40594-98-7).
Ethyl 1H-1,2,3-triazole-5-carboxylate (cas: 40594-98-7) belongs to triazole derivatives. Triazoles exhibit substantial isomerism, depending on the positioning of the nitrogen atoms within the ring. Triazole growth retardants such as uniconazole and paclobutrazol have been known to inhibit the biosynthesis of gibberellins by blocking kaurene oxidase, an P450 enzymeRecommanded Product: 40594-98-7
Referemce:
1,2,3-Triazole – Wikipedia,
Triazoles – an overview | ScienceDirect Topics